Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALIBRATE-HF: CRD-4730 in heart failure with reduced ejection fraction
2025-525033-31-00Phase 2Authorised
- Sponsor
- Cardurion Pharmaceuticals
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing CRD-4730 with Placebo (2 arms). Primary endpoint: Composite Z-score at 24 weeks. Planned start Aug 2026; status: authorised.
02
Drugs
CRD-4730
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2025-525033-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525033-31-00.